0
0
On October 23, 2025, the FDA announced its approval of Blenrep for use alongside established therapies bortezomib and dexamethasone in treating adult patients with relapsed or refractory multiple myeloma, particularly those who have failed at least two prior treatment lines. This decision marks a significant restoration and expansion of treatment options after Blenrep’s withdrawal from the U.S. market in 2022 due to concerns over efficacy and safety. The drug’s green light follows robust evidence from the pivotal DREAMM-7 phase III trial, addressing a crucial need for new therapies as most patients eventually face relapse and diminishing responses to existing regimens.
Key Findings: Efficacy and Safety
The DREAMM-7 trial results were pivotal to the FDA’s decision. In patients who had received two or more prior lines of therapy, Blenrep in combination reduced the risk of death by 51%—hazard ratio (HR) 0.49, 95% confidence interval (CI): 0.32-0.76—versus a daratumumab-based triplet regimen (DVd). Median progression-free survival increased from 10.4 months in the comparator arm to 31.3 months in the Blenrep combination group, tripling patients’ chances of living without disease progression. At 36 months, the Blenrep group demonstrated a 74% overall survival rate, compared to 60% for Darzalex—a competing therapy. Notably, Blenrep showed potential to extend patients’ lives by an average of nearly three years compared to the alternatives.
Safety remains a clinical priority, with the new FDA approval supported by a Risk Evaluation and Mitigation Strategy (REMS) that streamlines monitoring and reduces administrative burdens around patient eye care, a known area of risk due to possible ocular side effects. The combination’s overall safety profile was consistent with existing data on individual agents, but clinicians must remain vigilant for eye-related adverse events, which previously contributed to regulatory hesitance.
Expert Perspectives
Tony Wood, Chief Scientific Officer at GSK, highlighted the approval as “a significant milestone providing potential for superior efficacy including overall survival”. Dr. Sagar Lonial, Chief Medical Officer at Winship Cancer Institute, Atlanta, noted, “With the approval of Blenrep, we now have a community-accessible BCMA-targeting agent with the potential to improve outcomes for patients following two or more prior lines of treatment, where options are limited”. Both experts underscored the critical need for innovative treatments in a landscape where therapeutic resistance and relapse are nearly universal among patients.
Independent clinicians not involved in the research echoed these sentiments. Dr. Jonathan Cohen, hematologist at Emory University, noted, “The DREAMM-7 data suggest a meaningful clinical benefit for patients who have exhausted conventional therapies. The risk reduction in death and increased progression-free time can significantly impact patient quality of life, although careful monitoring remains essential.”
Context: Blood Cancer and Multiple Myeloma
Multiple myeloma is the third most common blood cancer, accounting for significant morbidity among adults worldwide. While the disease remains incurable, advances in targeted therapy have incrementally improved survival, turning a once universally fatal diagnosis into a chronic, manageable condition for some. However, almost all patients eventually relapse, making each new therapy critical for extending life expectancy and improving quality of life.
Blenrep was initially launched as a first-in-class anti-BCMA agent, designed to target a protein present on malignant plasma cells. Despite initial promise, the drug encountered setbacks—including its 2022 market withdrawal—owing to insufficient demonstration of survival benefit over competitors and notable side effects, primarily involving ocular toxicity.
Implications for Public Health
The FDA’s decision signals a paradigm shift in myeloma management, especially for underserved patients. Blenrep is now the only anti-BCMA therapy accessible in community settings, increasing the reach of cutting-edge treatment to the roughly 70% of patients who do not attend major medical centers. Moreover, streamlined REMS procedures facilitate easier therapy access while maintaining necessary safeguards.
Practical implications for patients include expanded choices after standard therapies fail and the possibility of longer remission periods. For healthcare providers, this approval brings renewed optimism—tempered by the need for ongoing surveillance of adverse effects, particularly eye toxicity.
Limitations and Counterarguments
Despite compelling trial results, experts caution that Blenrep is not without drawbacks. The risk for ocular side effects remains, and the long-term balance of benefit versus harm requires careful post-marketing surveillance. Further, while the trial showed a robust reduction in death and disease progression, not all patients may respond similarly, and the median survival period is still being tracked for final outcomes. Importantly, Blenrep is currently approved only for patients who have failed at least two prior lines of therapy, limiting its use to more advanced or challenging cases.
Diverse perspectives within the hematology field reflect optimism tempered by caution, emphasizing the drug’s role as a valuable option—not a universal solution.
What This Means for Readers
For individuals living with multiple myeloma—or those supporting loved ones—these developments provide cautious hope for longer, healthier lives in the face of a relentless disease. Readers should be aware that not all patients may be candidates for Blenrep, and therapy should always be discussed with qualified healthcare professionals. Vigilance about side effects, especially ocular symptoms, is essential.
Medical Disclaimer
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
